Cresco Labs (CL) EGM 2025 summary
Event summary combining transcript, slides, and related documents.
EGM 2025 summary
19 Jan, 2026Opening remarks and agenda
Meeting called to order with rules for virtual participation and electronic voting outlined.
Notice of meeting and related materials were distributed to shareholders of record as of August 1, 2025.
Quorum confirmed and meeting declared properly constituted.
Specific resolutions to be voted on
Fixing the number of directors at seven.
Election of directors as nominated in the Management Information Circular.
Appointment of Baker Tilly U.S., LLP as auditor for the ensuing year and authorization for the board to fix remuneration.
Approval of the corporation's awards exchange program.
Corporate governance
Secretary and scrutineer appointed for the meeting.
Advance notice policy followed for director nominations.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cresco Labs
- Q4 2025 revenue was $162M with margin gains, but net loss was driven by impairment charges.CL
Q4 20255 Mar 2026 - All resolutions, including director elections and incentive plan changes, were approved.CL
EGM 20243 Feb 2026 - Q2 saw margin and cash flow gains, with growth expected as adult-use markets expand.CL
Q2 20242 Feb 2026 - Q3 2024 saw record cash flow, margin gains, and top market share amid strategic growth moves.CL
Q3 202415 Jan 2026 - Margin and cash flow gains drive growth and expansion despite revenue decline and tax charges.CL
Q4 202425 Dec 2025 - Vertically integrated U.S. cannabis operator launches multi-security shelf offering amid regulatory risks.CL
Registration Filing29 Nov 2025 - Q1 2025 delivered $166M revenue, strong cash flow, and market leadership despite margin pressure.CL
Q1 202525 Nov 2025 - Q2 2025 revenue hit $164M, 25% EBITDA margin, and debt refinancing supports future growth.CL
Q2 202523 Nov 2025 - Q3 2025 revenue hit $165M, with strong market share, improved cash flow, and debt refinancing.CL
Q3 202513 Nov 2025